

CURRICULUM VITAE

Ye-Fong Du, M.D.

PERSONAL

EDUCATION

- Sep 1999-June 2006 Bachelor of Medicine (equivalent to M.D. in U.S.A.)
College of Medicine, National Cheng Kung University, Tainan, Taiwan
- Sep 2013-Jan 2018 Master's degree. Gerontology
College of Medicine, National Cheng Kung University, Tainan, Taiwan

WORKING EXPERIENCE

- Apr 2008-Jul 2011 Resident, Department of Internal Medicine
Department of Internal Medicine, National Cheng Kung University Hospital,
Tainan, Taiwan
- Aug 2011-Jul 2013 Fellow in Endocrinology, Diabetes and Metabolism
Division of Endocrinology and Metabolism, Department of Internal Medicine,
National Cheng Kung University Hospital, Tainan, Taiwan

MEDICAL LICENSE

Taiwan, No. 039952, Sep 13, 2006

BOARD CERTIFICATION

- Diplomate No.009311, Internal Medicine, Taiwan, R.O.C. Dec 06, 2011
- Diplomate No.00628, Endocrinology and Metabolism, Taiwan, R.O.C. Sep 1, 2013
- Certificated Diabetes Educator No.006741, Taiwanese Association of Diabetes Educator. Apr 14, 2019

PROFESSIONAL APPOINTMENT

- Aug 2013 – present Attending Physician
Division of Endocrinology and Metabolism,
Department of Internal Medicine,
National Cheng Kung University Hospital, Tainan, Taiwan
- Feb 2021 – present Assistant Professor
Department of Medicine
College of Medicine, National Cheng Kung University, Tainan, Taiwan
- May 2025 – present Deputy Secretary General
The Endocrine Society of the Republic of China, Taiwan (ESROC)

MAJOR RESEARCH AREA

Continuous glucose monitoring, diabetes education, type 1 diabetes.

Publications

1. Kao YC, Liang YC, **Du YF**, Ou HY. Primary Aldosteronism Presenting as Dropped Head Syndrome With Hypokalemic Rhabdomyolysis: A Case Report. *Case Rep Endocrinol* . 2026 Apr 29;2026:6424516.
2. Chong KS, Lee YH, Chang YH, **Du YF**, Ou HT, Kuo SC. Economic burdens of type 1 diabetes and its complications: A nationwide, longitudinal analysis. *Diabetes Res Clin Pract* . 2025 Aug;226:112329.
3. Chi HI, **Du YF***, Rebound ketoacidosis in a patient with diabetic ketoacidosis using ultra-long-acting insulin. *J Clin Transl Endocrinol Case Rep*. Volume 36, 2025, 100190
*Corresponding author
4. Lu JY, Ou HY, Wu CZ, Yang CY, Jiang JY, Lu CH, Jiang YD, Chang TJ, Chang YC, Hsieh ML, Wu WC, Li HY, **Du YF**, Lin CH, Hung HC, Tien KJ, Yeh NC, Lee SY, Yu HI, Chang LM. A randomized trial on the effect of transcutaneous electrical nerve stimulator on glycemic control in patients with type 2 diabetes. *Sci Rep*. 2023 Feb 15;13(1):2662.
5. Chou HW, Hung HC, Lin CH, Lin AC, **Du YF**, Cheng KP, Li CH, Chang CJ, Wu HT, Ou HY. The Serum Concentrations of Hedgehog-Interacting Protein, a Novel Biomarker, Were Decreased in Overweight or Obese Subjects. *J Clin Med*. 2021 Feb 12;10(4):742.
6. Chou HW, Ou HY, Hung HC, Cheng KP, **Du YF***. Effect of low-dose pioglitazone on nonalcoholic steatohepatitis: a case report. *Formosan Journal of Endocrinology and Metabolism*. 2021;12:105–110.
*Corresponding author
7. Wang CC, Lin CH, Hung HC, Cheng KP, **Du YF**, Wu HT, Ou HY. Worsening profiles of cardiometabolic risk factors after thionamide treatment in Graves' disease: a one-year prospective cohort study. *Formosan Journal of Endocrinology and Metabolism*. 2020;11:47–55.
8. **Du YF**, Huang YP, Hung HC, Lin CH, Cheng KP, Wu HT, Hu CY, Wu CL, Ou HY. Time trend analysis of the prevalence and incidence of type 2 diabetes among patients with autosomal dominant polycystic kidney disease. *Formosan Journal of Endocrinology and Metabolism*. 2020;11:13–21.
9. Chiu CJ, Yu YC, **Du YF**, Yang YC, Chen JY, Wong LP, Tanasugarn C. Comparing a Social and Communication App, Telephone Intervention, and Usual Care for Diabetes Self-Management: 3-Arm Quasiexperimental Evaluation Study. *JMIR Mhealth Uhealth*. 2020 Jun 2;8(6):e14024.
10. Huang RL, Li CH, **Du YF**, Cheng KP, Lin CH, Hu CY, Wu JS, Chang CJ, Wu HT, Ou HY. Discovery of a role of the novel hepatokine, hepassocin, in obesity. *Biofactors*. 2020 Jan;46(1):100-105
11. Chiu CJ, Chou YH, Chen YJ, **Du YF***. Impact of New Technologies for Middle-Aged and Older Patients: In-Depth Interviews With Type 2 Diabetes Patients Using Continuous Glucose Monitoring. *JMIR Diabetes*. 2019 Feb 21;4(1):e10992.
*Corresponding author

12. Chiu CJ, **Du YF***. Longitudinal investigation of the reciprocal relationship between depressive symptoms and glycemic control: The moderation effects of sex and perceived support. *J Diabetes Investig. J Diabetes Investig.* 2019 May;10(3):801-808.
*Corresponding author
13. Ou HT, Lee TY, **Du YF**, Li CY. Comparative risks of diabetes-related complications of basal insulins: a longitudinal population-based cohort of type 1 diabetes 1999-2013 in Taiwan. *Br J Clin Pharmacol.* 2018 Feb;84(2):379-391.
14. Ou HY, Wu HT, Lin CH, **Du YF**, Hu CY, Hung HC, Wu P, Li HY, Wang SH, Chang CJ. The Hepatic Protection Effects of Hepassocin in Hyperglycemic Crisis. *J Clin Endocrinol Metab.* 2017 Jul 1;102(7):2407-2415.
15. Lin CH, Lee SY, Zhang CC, **Du YF**, Hung HC, Wu HT, Ou HY. Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway. *Drug Des Devel Ther.* 2016 Nov 1;10:3591-3597
16. Chiu CJ, Li SL, Wu CH, **Du YF**. BMI Trajectories as a Harbinger of Pre-Diabetes or Underdiagnosed Diabetes: an 18-Year Retrospective Cohort Study in Taiwan. *J Gen Intern Med.* 2016 Oct;31(10):1156-63.
17. **Du YF**, Ou HY, Beverly EA, Chiu CJ. Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. *Clin Interv Aging.* 2014 Nov 18;9:1963-80.
18. **Du YF**, Ou HY, Wu TJ, Huang SM. Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS). *J Intern Med Taiwan,* 2013 Jun 24; 3: 181-188.

Conference Abstracts

1. **Du YF**, Ou HY. Glucose pattern analysis in individuals with prediabetes. [Abstract]. In: *Proceedings of the 17th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD 2025) in conjunction with the 46th Annual Meeting of the Diabetes Association and the Endocrine Society of the R.O.C. (Taiwan);* 2025 Mar 28–30.
2. Tsai MJ, **Du YF**, Lin CH, Ou HY. Clinical Challenges: A Case Series of Fulminant Type 1 Diabetes. [Abstract]. In: *Proceedings of the 17th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD 2025) in conjunction with the 46th Annual Meeting of the Diabetes Association and the Endocrine Society of the R.O.C. (Taiwan);* 2025 Mar 28–30.
3. Huang BY, Huang SH, Chen JC, Ou HY, Cheng KP, Lin CH, Chen PY, **Du YF**. Acromegaly presenting as diabetic ketoacidosis – a case report. [Abstract]. In: *Proceedings of the 43rd Annual Meeting of the Endocrinology Society and the Diabetes Association of the R.O.C. (Taiwan);* 2022 Mar 19–20.
4. **Du YF**, Hu CY, Wu HT, Ou HY. The role of metformin and organic cation transporter 2 in management of renal cell carcinoma. [Abstract]. In: *Proceedings of the 42nd Annual Meeting of the Endocrinology Society and the Diabetes Association of the R.O.C. (Taiwan);* 2021 Mar 27–28.

5. Lin TC, **Du YF**, Lin CH, Ou HY. Diabetic ketoacidosis associated with increased level of lithium concentration – a case report. [Abstract]. In: *Proceedings of the 40th Annual Meeting of the Endocrinology Society and the Diabetes Association of the R.O.C. (Taiwan)*; 2019 Mar 30–31.
6. **Du YF**, Ou HY, Hung HC, Lee MC, Chiu CJ. Evaluation of glycemic control and self-efficacy among patients receiving continuous glucose monitoring with immediate counseling feedback compared with delayed counseling feedback. [Abstract]. In: *Proceedings of the 39th Annual Meeting of the Endocrinology Society and the Diabetes Association of the R.O.C. (Taiwan)*; 2018 Mar 10-11.
7. **Du YF**, Hung HC, Ou HY. Optimizing Glycemic Control in Tube-Fed Diabetic Patients with Continuous Glucose Monitoring. [Abstract]. In: *Proceedings of the 38th Annual Meeting of the Endocrinology Society and the Diabetes Association of the R.O.C. (Taiwan)*; 2017 April 8-9.
8. **Du YF**, Ou HY, Peng SL, Wu TJ, Huang SM. Nesidioblastosis presented with postprandial hypoglycemia – a case report. [Abstract]. In: *Proceedings of the Annual Meeting of the Endocrinology Society and the Diabetes Association of the R.O.C. (Taiwan)*; 2012 Sep:34–35.
9. **Du YF**, Hung HC, Chuang CH, Wu TJ. Thyroid storm with reversible multi-organ failure: a case report. [Abstract]. In: *Proceedings of the Annual Meeting of the Endocrinology Society and the Diabetes Association of the R.O.C. (Taiwan)*; 2012 Mar.

Other Publications / 中文著作

1. **杜業豐***. 妊娠糖尿病的血糖監測. *糖尿病家族季刊*. 2023 年 12 月；頁 8–11.
2. 沈宗郁、**杜業豐***. 控糖新武器 – 連續血糖監測. *醫療器材與技術創新通訊*. 2023 年 6 月；第 6 期.
3. **杜業豐***. 從連續血糖監測的歷史演進解析臨床指引. *社團法人中華民國糖尿病衛教學會會訊*. 2022 年 12 月；頁 31–34.
4. **杜業豐**. 從 CGM 圖像看胰島素治療的細節. *社團法人中華民國糖尿病衛教學會會訊*. 2021 年 3 月；頁 13–19.
5. **杜業豐**. 記憶空了 愛不止息：談糖尿病失智患者的照護. *社團法人中華民國糖尿病衛教學會會訊*. 2015 年 12 月；頁 15–19.

從數據到決策：使用 CGM 與幫浦科技達到智慧醫療

From data to decisions: Utilize CGM and pump technology for smarter care

杜業豐

成大醫院 杜業豐醫師

過去幾年，連續血糖監測（CGM）已經從「間歇使用、一次性解讀」轉變為「長期配戴、動態決策」。過去，病人難得完成一次 CGM 檢測，醫療人員傾向在單次報告中傳遞大量資訊；然而在現今 CGM 普及的情境下，重點已轉為協助病人與裝置長期共存，建立可持續的自我管理模式。

內容將聚焦於幾個核心面向：首先，辨識與克服 CGM 在實務上的技術限制（如感測延遲、個體差異與批次偏差）；其次，合理設定與運用警報系統，以降低警報疲乏並提升臨床決策價值；第三，強調在特定情境下以指尖血糖確認 CGM 數據，建立「校準信任」的概念；同時，重新調整病人與醫療人員對 CGM 數據的期待，避免過度反應或錯誤決策。

最終，透過結合 CGM 與胰島素幫浦技術，臨床重點將不再是全面性解讀所有數據，而是從每一次監測中精準辨識最具臨床意義的異常模式，作為醫病溝通與介入的切入點，實現以數據驅動的個人化智慧照護。